Imaniver (Imatinib)

Imatinib is used to treat malignancies driven by abnormal tyrosine‑kinase signaling.

• Chronic myeloid leukemia (CML): reduces disease progression and improves survival.
• Gastrointestinal stromal tumor (GIST): induces tumor regression and delays recurrence.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission when combined with chemotherapy.

• Imatinib selectively inhibits the ATP‑binding sites of BCR‑ABL, c‑KIT and platelet‑derived growth factor receptor (PDGFR) tyrosine kinases. By blocking these enzymes, it prevents downstream phosphorylation cascades that drive cell proliferation and survival, leading to apoptosis of malignant cells that depend on these signaling pathways. The inhibition is competitive and reversible, allowing dose‑dependent control of kinase activity and sparing normal hematopoietic cells at therapeutic concentrations.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools, often transient.
• Fatigue: generalized tiredness.
• Edema: peripheral swelling, especially around ankles.
• Muscle cramps: intermittent skeletal muscle discomfort.
• Rash: mild skin erythema.
• Headache: mild pain in head.
• Vomiting: occasional episodes.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiotoxicity: heart failure or reduced left ventricular function.
• Severe neutropenia: marked drop in white blood cells.
• Thrombocytopenia: low platelet count leading to bleeding risk.
• Pulmonary arterial hypertension: increased pressure in lung arteries.
• Anaphylaxis: rare severe allergic reaction.

When prescribing Imatinib, clinicians should observe several precautionary measures to minimize risk.

• Monitor liver function: perform baseline and periodic tests.
• Assess cardiac status: evaluate ejection fraction before and during therapy.
• Check blood counts: regular CBC to detect neutropenia or thrombocytopenia.
• Avoid concomitant strong CYP3A4 inhibitors: may increase plasma levels.
• Counsel patients on pregnancy risks: drug is contraindicated in pregnancy unless benefits outweigh risks.
• Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Imatinib interacts with several medicines that can alter its exposure or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can raise imatinib levels.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): can lower efficacy.
• Antacids containing aluminum or magnesium: reduce absorption if taken simultaneously.
• Concomitant use with grapefruit juice: can increase plasma concentration.

Moderate Interactions (Monitor Closely)

• Acid‑reducing agents (e.g., proton pump inhibitors): may modestly decrease bioavailability.
• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• CYP2C8 substrates (e.g., repaglinide): possible increased exposure.
• Diuretics (e.g., furosemide): may increase risk of electrolyte disturbances.